Sunday, May 14, 2017, Boston, MA — 8:00 AM – 10:00 AM (Eastern Time)

What Urologists Want to Know: Addressing Current Questions and Controversies in the Management of Early and Advanced Prostate Cancer

Location:
The Westin Boston Waterfront
425 Summer Street
Boston, MA 02210
Hotel Phone: (617) 532-4600

Time:
7:30 AM – 8:00 AM (Eastern Time) — Registration and Breakfast Buffet
8:00 AM – 10:00 AM (Eastern Time) — Educational Meeting

Meeting Room:
Harbor Ballroom (Conference Level)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
 
Faculty:
Raoul S Concepcion, MD
Director
The Comprehensive Prostate Center
Nashville, Tennessee

Leonard G Gomella, MD
The Bernard W Godwin
Professor of Prostate Cancer
Chairman, Department of Urology
Associate Director
Jefferson Sidney Kimmel Cancer Center
Clinical Director, Jefferson Sidney Kimmel
Cancer Center Network
Editor-in-Chief, Canadian Journal of Urology
Philadelphia, Pennsylvania

Daniel W Lin, MD
Professor and Chief of Urologic Oncology
Department of Urology
Bridges Endowed Professorship in Prostate Cancer Research
University of Washington
Seattle, Washington


David I Quinn, MBBS, PhD
Medical Director
Norris Cancer Hospital and Clinics
Head, GU Cancer Section
Division of Cancer Medicine and Blood Diseases
USC/Norris Comprehensive Cancer Center
Los Angeles, California

A Oliver Sartor, MD
Medical Director, Tulane Cancer Center
Laborde Professor of Cancer Research
Professor of Medicine and Urology
Tulane Medical School
New Orleans, Louisiana

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

MODULE 1: Available and Emerging Biomarkers to Inform Decision-Making for Patients with Early-Stage Prostate Cancer (PC) and Use of Active Surveillance — Dr Concepcion

Presentation and Discussion Topics

  • Available and investigational applications of PSA-based testing to improve PC detection rates (eg, PSA kinetics, free/total PSA, PSA isoforms)
  • Clinical utility of available and emerging biomarkers to detect the potential presence of PC in patients at risk, including those undergoing active surveillance (eg, PCA3, ConfirmMDx®, SelectMDx®, PHI, 4Kscore®, TMPRSS2-ERG fusion)
  • Development, reference genes and published validation studies of commercially available molecular assays (eg, Prolaris®, Oncotype DX®, ProMark®) designed to enhance risk assessment and inform primary decision-making for patients with newly diagnosed PC
  • Interpretation of the Genomic Prostate Score (GPS), Prolaris Score, SelectMDx, PHI and ProMark Report results and use in individual patient counseling regarding long-term recurrence risk and therapeutic selection
  • Indications for and optimal implementation of active surveillance for patients with a positive PC biopsy; role of genomic classifiers to inform this decision
  • Available data on the use of molecular profiling assays (eg, Prolaris, Decipher®) to assess the risk of developing clinical metastases after radical prostatectomy
  • Role of genetic testing for inherited PC risk: Common genetic mutations (eg, BRCA) contributing to increased risk of PC and implications for disease prognosis and management

MODULE 2: Optimal Integration of Chemotherapy into the Management of Endocrine

Presentation and Discussion Topics

  • Similarities and differences in the design and results of the CHAARTED and STAMPEDE trials evaluating the use of docetaxel for patients with hormone- sensitive metastatic PC
  • Risks and benefits documented with the use of up-front docetaxel in combination with androgen deprivation therapy (ADT) for patients with hormone-sensitive disease; patient selection for this approach in clinical practice
  • Impact of CHAARTED and STAMPEDE trial results on referral patterns among community-based urologists and radiation and medical oncologists
  • Clinical investigator perspectives on the use of concomitant corticosteroids or bone-targeted therapy for patients with hormone-sensitive metastatic PC receiving docetaxel
  • Earlier docetaxel use and the utility of and indications for cytotoxic therapy in patients with metastatic castration-resistant PC (mCRPC)
  • Risks and potential benefits of combining docetaxel with ADT for select patients with PSA-only disease

MODULE 3: Sequence and Selection of Systemic therapy for Patients with mCRPC — Dr Quinn

Presentation and Discussion Topics

  • Relevance of age, performance status, symptomatology and prior therapeutic exposure/response in the selection and sequencing of secondary hormonal therapy, immunotherapy and cytotoxic therapy
  • Long-term safety and efficacy data with secondary hormonal agents in chemotherapy-naïve and pretreated mCRPC
  • Available research information and ongoing evaluation of androgen receptor splice variant 7 (AR-V7) as a biomarker to predict resistance to secondary hormonal therapy
  • Patient selection for sipuleucel-T in clinical practice; effects of tumor burden/extent of disease on its clinical utility
  • Rapidity of response associated with the use of second-generation androgen inhibitors and sipuleucel-T; use of these therapies versus chemotherapy for symptomatic disease
  • Active clinical trials evaluating other novel agents (eg, apalutamide) and strategies (eg, abiraterone acetate [AA] with sipuleucel-T) in mCRPC

MODULE 4: Role of Bone-Targeted therapies Across the PC Continuum — Dr Sartor

Presentation and Discussion Topics

  • Lingering clinical controversies regarding the optimal use of bisphosphonates and/or RANK ligand inhibition in the management of metastatic and nonmetastatic PC
  • Role of palliative radiation therapy in the management of symptomatic skeletal metastases
  • Similarities and differences between radium-223 and other radiopharmaceuticals (eg, 153Sm-EDTMP and strontium-89)
  • Available efficacy and safety data with radium-223 in mCRPC; antitumor and bone-protective activity documented in clinical trials
  • Current indications for the use of radium-223 in clinical practice and logistics of administration; practical considerations and coordination of care for patients commencing radium-223 therapy
  • Ongoing evaluation of radium-223 in combination with secondary hormonal therapy for patients with skeletal metastases

MODULE 5: Ongoing Investigation and Potential Integration of Secondary Hormonal therapy, Immunotherapy or Cytotoxic therapy into the Management of Earlier-Stage Disease — Dr Gomella

Presentation and Discussion Topics

  • Preliminary efficacy and safety data and ongoing evaluation of second-generation androgen inhibitors (AA, enzalutamide) as neoadjuvant or adjuvant therapy for patients with “high-risk” localized PC
  • Emerging research data (STRIVE, IMAAGEN trials, et cetera) documenting the utility of secondary hormonal agents for patients with nonmetastatic CRPC; current clinical implications, if any
  • Available research data (STAND, PROTECT trials) examining the use of sipuleucel-T in patients with biochemically recurrent nonmetastatic PC; current nonresearch indications, if any
  • Ongoing Phase III trials of enzalutamide alone (PROSPER) or in combination with LHRH agonist therapy (EMBARK) for patients with nonmetastatic PC
  • Emerging data from the Phase III LATITUDE trial evaluating ADT alone or with AA and prednisone in newly diagnosed high-risk metastatic hormone-naïve PC.
  • Mechanism of action, available research data and ongoing Phase III investigations of the novel antiandrogens apalutamide and darolutamide in high-risk localized PC (ATLAS trial), nonmetastatic CRPC (SPARTAN, ARAMIS trials) and hormone-sensitive metastatic disease (ARASENS trial)

Target Audience:
This activity has been designed to meet the educational needs of medical oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.

Learning Objectives and Goals:
At the conclusion of this activity, participants should be able to:

  • Review existing and emerging research data evaluating the use of novel biomarkers and gene signatures to refine risk of recurrence for patients with localized prostate cancer, and use the results from available molecular assays to guide clinical decision-making.
  • Evaluate emerging clinical trial evidence with the use of available and investigational secondary hormonal agents in the management of nonmetastatic prostate cancer, and consider this information in the discussion of protocol and nonresearch treatment options.
  • Explore published research information on the use of cytotoxic therapy in the setting of hormone-sensitive advanced prostate cancer, and refer appropriate candidates for consultation with a medical oncologist to discuss the risks and benefits of this approach.
  • Compare and contrast the efficacy and safety of denosumab and bisphosphonates in the treatment and/or prevention of prostate cancer skeletal metastases.
  • Consider available research data and expert perspectives on the efficacy and safety of radium-223 chloride as monotherapy or in combination with other treatment modalities, and use this information to appropriately integrate this novel radiopharmaceutical agent into current nonresearch treatment algorithms.
  • Effectively apply evidence-based research findings in the determination of best-practice sequencing of available immunotherapeutic, chemotherapeutic and secondary hormonal agents for patients with metastatic prostate cancer.
  • Counsel appropriately selected patients with prostate cancer about the availability of and participation in ongoing clinical trials.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
This activity is supported by educational grants from Astellas Pharma Global Development Inc/Medivation Inc, a Pfizer Company, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Genomic Health and Sanofi Genzyme.

The Westin Boston Waterfront
425 Summer Street
Boston, MA 02210
Hotel Phone: (617) 532-4600

Meeting Room:
Harbor Ballroom (Conference Level)

Directions:
The Westin Boston Waterfront hotel is connected to the Boston Convention and Exhibition Center.

 

This activity has been designed to meet the educational needs of medical oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/ industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in with our on-site registration desk at least 30 minutes prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.